Fluoroquinolones: risk of mitral and aortic regurgitation associated with the use of oral and injectable fluoroquinolones

Fluoroquinolones: risk of mitral and aortic regurgitation associated with the use of oral and injectable fluoroquinolones

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the companies listed below would like to inform you about the risk of mitral and aortic regurgitation that should be taken into consideration when prescribing oral fluoroquinolone antibiotics.

2020 Jun

Download latest version
File Type: pdf
Category: Communication To Health Care Professionals
Unit: pharmacovigilance